The pitch sounds deceptively simple: What if India's mid-sized hospitals could buy reliable anaesthesia machines and blood tubing sets from domestic manufacturers instead of waiting months for shipments from Germany or China?
That's the question animating Pulse, a year-old Bengaluru startup that just closed $4 million in seed funding. The round, led by 3one4 Capital with backing from Incubate Fund Asia, Stride Ventures, and a handful of angel investors—including the founders of logistics platform BlackBuck and agricultural startup Agrizy—was announced in late February. The company's post-money valuation settled around ₹36.38 crore, a modest sum that reflects both the early stage and the immense challenge ahead.
Founded by Anshul Sharma and Nishant Goel, both alumni of Zetwerk's manufacturing networks, Pulse bills itself as India's first horizontal original equipment manufacturer platform for medical technology. The founders aren't building factories. Instead, they're orchestrating a network of nearly 20 small and medium manufacturers scattered across Delhi NCR, Jammu, Gujarat, Kolkata, and Mumbai. Through these partners, Pulse produces critical care, renal care, and cardiac care equipment—the unglamorous workhorses of hospital operations.
Why This Matters Now
India imports somewhere between 70 and 80 percent of its medical devices, a dependency that became painfully visible during pandemic-era supply chain disruptions. Government officials have been talking about localizing production for years. But talk is cheap. Execution is another matter entirely.
Pulse targets what you might call the middle market of Indian healthcare: hospitals with 50 to 200 beds that can't afford Siemens or GE pricing but need equipment that won't fail during surgery. The value proposition, according to 3one4 Capital's investment memo, is "deliberate, affordable premium"—devices that meet global compliance standards while undercutting Western incumbents by 30 to 40 percent.
Whether that math actually works in practice remains an open question.
The company's 25-person team doesn't manufacture much itself. Instead, it layers intellectual property, quality systems, regulatory certifications, and after-sales service atop its manufacturing network. According to 3one4's publicly stated thesis, Pulse aims to complete 40 to 50 structured technology transfers over the next five years. The goal: compress the typical 24- to 36-month product development cycle down to somewhere between 8 and 15 months.
Ambitious? Certainly. The medical device business is notoriously unforgiving when it comes to regulatory hurdles and quality control. A single recall can sink a startup.
The Visakhapatnam Gambit
A chunk of the fresh capital is earmarked for an R&D and manufacturing facility at Andhra Pradesh's Medical Technology Zone in Visakhapatnam. Reports from The Economic Times suggested the facility might become operational as early as March, though the company hasn't publicly confirmed that timeline. (Perhaps it's operational now; perhaps it's been delayed. Startups and construction deadlines rarely align perfectly.)
Beyond bricks and mortar, Pulse plans to accelerate product development, secure additional regulatory certifications, and expand distribution channels. The startup is also betting on recurring revenue from annual maintenance contracts—targeting 20 to 25 percent of total revenue at gross margins between 50 and 70 percent as its installed base grows. It's the classic razor-and-blades model, applied to medical equipment.
And then there's the export ambition. From year one, Pulse has its eye on Southeast Asia and Africa, markets where Chinese manufacturers currently dominate. The founders believe stronger service capabilities—something Chinese competitors don't always prioritize—will give them an edge.
Investor Enthusiasm, Tempered by Reality
"The opportunity lies in building a dependable, India-made alternative that doesn't compromise on quality," said Akshay Sharma, a principal at 3one4 Capital, in a statement accompanying the funding announcement. Rajeev Ranka, India partner at Incubate Fund Asia, struck a similar note: "There's a clear need for reliable and affordable equipment manufactured locally."
The investor conviction reflects broader momentum. Recent expansions at the Visakhapatnam zone—including what's been billed as the world's largest X-ray imaging components facility—signal that domestic capability is improving. Industry projections, based on data from the India Brand Equity Foundation compiled through mid-2025, peg the sector's value at roughly $50 billion by decade's end.
Still, projections are just that. India's medtech sector has long been heavy on ambition and light on execution.
What Success Looks Like
Pulse has been quietly hiring salespeople in Bangalore since January, according to job postings—a sign that the commercial push is underway. The company is starting with critical care devices, then plans to expand across specialties and eventually serve larger hospital chains.
Whether Pulse can actually compress product development timelines and execute technology transfers at the pace its investors expect is the central question. Medical devices aren't software. You can't iterate your way out of a regulatory bottleneck or a manufacturing defect. Quality control in this sector is measured in lives, not uptime percentages.
But the startup enters a market where import dependence creates both urgency and opportunity. A growing number of domestic manufacturers—many clustered around government-backed zones like the one in Visakhapatnam—are attempting to fill the gap. Some will succeed. Many won't.
For now, Pulse has capital, a network, and a clear thesis. The hard part—delivering equipment that works, consistently, at scale—comes next.
